Cargando…

Vinorelbine and Intermittent Cyclophosphamide Sensitize an Aggressive Myc-Driven B-Cell Lymphoma to Anti-PD-1 by an Immunological Memory Effective against Tumor Re-Challenge

We have previously shown in triple-negative breast cancer (TNBC) models that a triple therapy (TT) including intermittent cyclophosphamide (C), vinorelbine (V), and anti-PD-1 activates antigen-presenting cells (APC) and generates stem like-T cells able to control local and metastatic tumor progressi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Orecchioni, Stefania, Falvo, Paolo, Talarico, Giovanna, Mitola, Giulia, Bravetti, Giulia, Mancuso, Patrizia, Nicoli, Paola, Bertolini, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095342/ https://www.ncbi.nlm.nih.gov/pubmed/37048617 http://dx.doi.org/10.3390/jcm12072535

Ejemplares similares

Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma
por: Orecchioni, Stefania, et al.
Publicado: (2018)

A “two-hit” (chemo)therapy to improve checkpoint inhibition in cancer
por: Falvo, Paolo, et al.
Publicado: (2021)

A single-cell transcriptomic landscape of innate and adaptive intratumoral immunity in triple negative breast cancer during chemo- and immunotherapies
por: Carpen, Laura, et al.
Publicado: (2022)

New Insight to Overcome Tumor Resistance: An Overview from Cellular to Clinical Therapies
por: Mitola, Giulia, et al.
Publicado: (2021)

Comparison of CVF (Cyclophosphamide+Vinorelbine+5-Fluorouracil) and CMF (Cyclophosphamide+Methotrexate+5-Fluorouracil) Adjuvant Chemotherapy in Early Breast Cancer
por: Gwak, Geumhee, et al.
Publicado: (2011)

Oral vinorelbine and continuous low doses of cyclophosphamide in pediatric rhabdomyosarcoma: a real-world study
por: Lan, Yingxia, et al.
Publicado: (2023)

Study on Effects of Cyclophosphamide Combined with Vinorelbine in Advanced Small Cell Lung Cancer and Anteroposterior Changes in MRI
por: Li, Zhichun, et al.
Publicado: (2022)

Metformin sensitizes leukemic cells to cytotoxic lymphocytes by increasing expression of intercellular adhesion molecule-1 (ICAM-1)
por: Allende-Vega, Nerea, et al.
Publicado: (2022)

Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells
por: Talarico, Giovanna, et al.
Publicado: (2016)

The metabolism of cells regulates their sensitivity to NK cells depending on p53 status
por: Belkahla, Sana, et al.
Publicado: (2022)

Vinorelbine – a clinical review
por: Gregory, R K, et al.
Publicado: (2000)

Oral vinorelbine in metastatic breast cancer
por: Conte, PF, et al.
Publicado: (2005)

Vinorelbine Augments Radiotherapy in Hepatocellular Carcinoma
por: Yeoh, Kheng Wei, et al.
Publicado: (2020)

A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer
por: Yoo, Changhoon, et al.
Publicado: (2015)

Oral vinorelbine versus intravenous vinorelbine, in combination with epirubicin as first-line chemotherapy in Chinese patients with metastatic breast cancer
por: Huang, Liang, et al.
Publicado: (2019)

Epigenetics, c-Myc and Aggressive B-cell Lymphomas
por: Zhang, Yizhuo, et al.
Publicado: (2012)

A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study
por: Vici, Patrizia, et al.
Publicado: (2011)

Establishment of patient derived xenografts as functional testing of lung cancer aggressiveness
por: Moro, Massimo, et al.
Publicado: (2017)

Vinorelbine induced perforation of a metastatic gastric lesion
por: Mullally, W. J., et al.
Publicado: (2016)

Carboplatin/vinorelbine: Worsening of lung adenocarcinoma: case report
Publicado: (2022)

Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial
por: Li, Dou-Dou, et al.
Publicado: (2022)

Author Correction: Establishment of patient derived xenografts as functional testing of lung cancer aggressiveness
por: Moro, Massimo, et al.
Publicado: (2018)

Reactivity of the immunological system of rats stimulated with Biolex-Beta HP after cyclophosphamide immunosuppression
por: Wójcik, Roman
Publicado: (2014)

Methods of preventing vinorelbine-induced phlebitis: an experimental study in rabbits
por: Kohno, Emiko, et al.
Publicado: (2008)

Comparison of vinorelbine with cisplatin in concomitant chemoradiotherapy in head and neck carcinoma
por: Devleena,, et al.
Publicado: (2010)

Effect of ethnicity on vinorelbine pharmacokinetics: a population pharmacokinetics analysis
por: Pétain, Aurélie, et al.
Publicado: (2019)

PB2161: CHARACTERISTICS OF AGGRESSIVE B-CELL LYMPHOMAS WITH MYC REARRANGEMENT
por: Ortuzar Pasalodos, A., et al.
Publicado: (2022)

Studies of the effects and mechanisms of ginsenoside Re and Rk(3) on myelosuppression induced by cyclophosphamide
por: Han, Jiahong, et al.
Publicado: (2019)

Intermittent aspiration of pharyngeal secretion for re-intubation prevention
por: Nakamura, T, et al.
Publicado: (2012)

Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group
por: Fløtten, Ø, et al.
Publicado: (2012)

Combined use of apatinib mesylate and vinorelbine versus vinorelbine alone in recurrent or metastatic triple-negative breast cancer: study protocol for a randomized controlled clinical trial
por: Wu, Shuo, et al.
Publicado: (2020)

Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study
por: Wang, L L, et al.
Publicado: (2015)

Cellular and Molecular Players in the Interplay between Adipose Tissue and Breast Cancer
por: Reggiani, Francesca, et al.
Publicado: (2021)

MYC chromosomal aberration in differential diagnosis between Burkitt and other aggressive lymphomas
por: Aquino, Gabriella, et al.
Publicado: (2013)

Interplay: The Essential Role between INSM1 and N-Myc in Aggressive Neuroblastoma
por: Chen, Chiachen, et al.
Publicado: (2022)

IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma
por: Pisano, Michael D., et al.
Publicado: (2023)

Comparative study of the radiosensitising and cell cycle effects of vinflunine and vinorelbine, in vitro
por: Simoens, Cindy, et al.
Publicado: (2008)

Safety and Efficacy of Vinorelbine in the Treatment of Non-Small Cell Lung Cancer
por: Faller, Bryan A., et al.
Publicado: (2011)

A Timely Oral Option: Single‐Agent Vinorelbine in Desmoid Tumors
por: Gennatas, Spyridon, et al.
Publicado: (2020)

LINC-26. ORAL VINORELBINE IN PROGRESSIVE UNRESECTABLE LOW-GRADE GLIOMA
por: Cappellano, Andréa M, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tgl9883bda3l50jk03iep6364e